Immodulon Therapeutics announce Orphan Drug Designation for IMM-101 in US in the treatment of pancreatic cancer

LONDON, UK – September 23, 2014 - Immodulon Therapeutics today announced that Orphan designation was granted by the FDA for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.

Click here to view public summary